Publications by authors named "Machiko Shiroishi"
Article Synopsis
- Mixed lineage leukemia 1-rearranged (MLL1-r) acute leukemia patients have poor treatment responses, necessitating the development of therapies that disrupt the Menin-MLL1 complex, such as the compound DS-1594a.
- Preclinical evaluations showed that DS-1594a and its salts effectively inhibited the growth of MLL1-r or NPM1c leukemic cells, outperforming traditional chemotherapy like cytrabine in in vitro and in vivo models.
- DS-1594a, with its potent antitumor effects, suggests potential as a new oral anticancer therapy, distinct from existing treatments, offering hope for improved outcomes in acute leukemia patients.
Polycomb repressive complex 2 (PRC2) methylates histone H3 lysine 27 and represses gene expression to regulate cell proliferation and differentiation. Enhancer of zeste homolog 2 (EZH2) or its close homolog EZH1 functions as a catalytic subunit of PRC2, so there are two PRC2 complexes containing either EZH2 or EZH1. Tumorigenic functions of EZH2 and its synthetic lethality with some subunits of SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling complexes have been observed.
View Article and Find Full Text PDFNovel, cell-based assays, based on bioluminescence resonance energy transfer, have been developed for FcepsilonRI- and GPVI-FcRgamma complex-mediated signaling at receptor-proximal steps. In a stable transfectant of the HEK-293 cell line expressing human FcepsilonRIalpha, FcepsilonRIbeta, and FcRgamma-GFP2 and Syk(1-265)-Rluc fusion proteins, FcepsilonRI cross-linking markedly increased BRET2 ratios, which are the ratios of GFP2 emission to Rluc emission. These ratios reflect the FcRgamma-GFP2-Syk(1-265)-Rluc interaction in living cells.
View Article and Find Full Text PDF